Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion

Arutyunov, G. P.; Boytsov, S. А.; Воевода, М. И.; Drapkina, О. М.; Кухарчук, В. В.; Мартынов, А. И.; Shestakova, Marina Vladimirovna; Gurevich, V. S.; Сергиенко, И. В.; Alieva, A.; Ахмеджанов, Н. М.; Бубнова, М. Г.; Galyavich, А. S.; Гордеев, И. Г.; Yezhov, M. V.; Karpov, Yu. A.; Константинов, В. О.; Недогода, С. В.; Nifontov, E. M.; Orlova, Yа A; Panov, A. V.; Сайганов, С А; Skibitsky, V. V.; Tarlovskaya, E. I.; Urazgildeeva, S. A.; Khalimov, Yu. Sh.

doi:10.15829/1560-4071-2019-9-44-51

Cited by 10 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Проблеме сердечно-сосудистого риска (ССР) с учетом ее высокой распространенности в последнее время придается большое значение. Как отмечено в публикации российских исследователей [1], к 2030г от сердечно-сосудистых заболеваний (ССЗ) ежегодно будут умирать ~23,6 млн человек. В клинических и эпидемиологических исследованиях установлена прочная связь гипер-и дислипидемии с сердечно-сосудистыми осложнениями (ССО) [2,3].…”

Section: Association Of Hypertriglyceridemia With Risk Factors For Ca...unclassified

Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk

et al. 2023

View full text Add to dashboard Cite

Aim. To study clinical and functional manifestations of hypertriglyceridemia and its association with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk.Material and methods. The study included 272 patients (129 men and 143 women; mean age, 53,9±13,7 years) with a high cardiovascular risk, which was stratified using Systematic Coronary Risk Evaluation (SCORE) model by the presence of cardiovascular disease, and/or diabetes, and/or age ≥65 years, and/or blood pressure (BP) >180/110 mm Hg, and/or total cholesterol (TC) level >8,0 mmol/l. All study participants underwent clinical and paraclinical examination. Serum content of triglycerides (TGs) ≥1,7 mmol/L was considered hypertriglyceridemia (HTG). Depending on TG level, the entire sample was divided into 2 following subgroups: subgroup 1 (n=178) — serum triglycerides ≤1,6 mmol/l; subgroup 2 (n=94) — serum triglycerides ≥1,7 mmol/l, i.e. HTG.Results. We revealed significantly more persons with obesity (46,8%) and type 2 diabetes (28,7%) in HTG subgroup. There were 56,3% and 36,1% patients of HTG subgroup with hypertension (HTN) and coronary artery disease (CAD), respectively. A mid-high TG level (from 1,7 to 2,3 mmol/l) in the subgroup of patients with HTG was detected in 38,3% of cases. The serum content of TG from 2,3 to 5,6 mmol/l was detected in 54,2% of patients. TG level ≥5,6 mmol/l was detected in 7,5% of cases. In the subgroup of patients with HTG, high levels of systolic, diastolic and central (aortic) BP, body mass index, phosphorus, creatinine, cystatin C, estimated glomerular filtration rate (eGFR), and carotid intima-media thickness (IMT) were detected significantly more common. In the general sample, a significant direct relationship between TG concentration and cystatin C (r=0,168) and an inverse (negative) relationship with eGFR (r=-0,220) was obtained.Conclusion. Elevated serum TG levels are often observed in individuals with obesity, type 2 diabetes, hypertension and CAD. Patients with HTG had a pronounced cardiovascular and renal risk, including a significant increase in BP and carotid IMT, high levels of total cholesterol, low-density lipoprotein cholesterol, phosphorus, creatinine, cystatin C, and a decrease in eGFR. HTG was associated with an increase in serum cystatin C and a deterioration in renal nitrogen excretion.

show abstract

Section: Association Of Hypertriglyceridemia With Risk Factors For Ca...unclassified

Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Кроме того, показано, что применение фибратов в сочетании со статинами повышает риск развития миопатии [5]. Фибраты служат препаратами выбора у больных с редко встречающимися формами гиперлипидемии в сочетании с высоким уровнем ТГ, а также показаны пациентам с инсулиннезависимым сахарным диабетом при гипертриглицеридемии и сниженным содержанием ЛПВП [5,7,28,29]. Актуальность назначения фенофибрата обусловливает его наличие в перечне ЖНВЛП на 2023 г.…”

Section: эффективность и безопасность фибратовunclassified

“…Безопасность препаратов подтверждается тем, что даже длительный прием ω-3-ПНЖК в дозах от 1,0 до 3,0 г в большинстве случаев переносится без нежелательных эффектов, однако при наличии индивидуальной непереносимости рыбных продуктов возможно возникновение аллергических реакций [29].…”

Section: таблица 2 сравнительная характеристика гиполипидемических пр...unclassified

“…Таким образом, положительное влияние ω-3-ПНЖК на липидный обмен позволяет рекомендовать их для профилактики и лечения ССЗ [29]. Однако полученные доказательства эффективности обусловливают применение лишь в комплексной терапии со статинами у пациентов с высоким и очень высоким риском, с уровнем ТГ 1,5-5,6 ммоль/л, в высокой дозе 4 г/сут (уровень рекомендаций IIaB) [18].…”

Section: таблица 2 сравнительная характеристика гиполипидемических пр...unclassified

See 1 more Smart Citation

Assessment of the global and national market for lipid modifying agents: retrospective and innovation

Lokhmacheva,

Fominykh,

Trubina

et al. 2023

Sibirskij nauchnyj medicinskij zhurnal

View full text Add to dashboard Cite

Lipid-lowering therapy is one of the most important aspects in the treatment of patients with cardiovascular disease, which is still the leading cause of death in the adult population. Over the past 10 years, fundamentally new lipid-lowering drugs have appeared such as alipogene tiparvovec, mipomersen, lomitapide, evolocumab, alirocumab, bempedoic acid, inclisiran, evinacumab, volanesorsen. In order to update information on the effectiveness and safety of the use of lipidlowering drugs, their consumption in the pharmaceutical market in retrospect and at the present time, a systematic search was carried out in the scientific databases eLIBRARY.RU, PubMed, Embase, ClinicalTrials.gov, the Cochrane Library, Russian State Register of Medicines from 1980 to 2023. Statins remain the main drugs of choice for regular use in violation of lipid metabolism. Fibrates are the drugs of choice in patients with rare forms of hyperlipidemia associated with high triglyceride level. A group of other lipid-lowering drugs has been characterized from the point of view of the mechanisms of action, indications for use, and the availability of registration certificates in the Russian Federation and in the world. The growing interest in ezetimibe in the Russian pharmaceutical market is confirmed by the high growth in the share of local companies in its production as part of the import substitution strategy. It has been established that the drug causes undesirable effects with a small degree of probability as part of combination therapy. Inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) open up new possibilities for the treatment of patients at very high risk of cardiovascular disease. Lomitapide is not registered in the Russian Federation, but since December 2021 it has been included in the list of medicines purchased by the Krug Dobra Foundation to help children with homozygous familial hypercholesterolemia. Since 2022, inclisiran, a drug inhibiting synthesis of PCSK9 with RNA interference, has been approved for use in Russia and is safe in patients with hyperlipidemia and statin intolerance. Thus, in the 21st century, fundamentally new positions have appeared in the group of lipid-lowering drugs, which are examples of biotechnological and gene therapy drugs.

show abstract

“…• Всем пациентам с ИБС или подозрением на нее рекомендуется провести анализ крови для оценки нарушений липидного обмена, биохимический, включая исследование уровня общего холестерина (ОХС) крови, уровня холестерина (ХС) липопротеидов низкой плотности (ХС ЛНП) и триглицеридов [22] [23][24][25].…”

Section: еок Ib (уур с удд 5)unclassified

2020 Clinical practice guidelines for Stable coronary artery disease

общество¹

2020

Russ J Cardiol

139

View full text Add to dashboard Cite

show abstract

Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion

Cited by 10 publications

References 39 publications

Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk

Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk

Assessment of the global and national market for lipid modifying agents: retrospective and innovation

2020 Clinical practice guidelines for Stable coronary artery disease

Contact Info

Product

Resources

About